FGF 21 polypeptides comprising two or more mutations and uses thereof
AssigneeAmgen Inc.
InventorsEdward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
Life of this patent
Estimating the term…
Abstract
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Claims18
An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:
- 4 and further comprising an amino acid substitution at position 180;
- and an amino acid substitution at position 98 of SEQ ID NO:4,—wherein,
- (a) the amino acid residue at position 98 is arginine, and
- (b) the amino acid residue at position 180 is selected from the group consisting of glycine, proline, serine or glutamic acid.
An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:
- 4 and further comprising an amino acid substitution at position 180;
- and an amino acid substitution at position 98 of SEQ ID NO:4,—wherein,
- (a) the amino acid residue at position 98 is arginine, and
- (b) the amino acid residue at position 180 is selected from the group consisting of glycine, proline, serine or glutamic acid.
Dependencies are inferred from the claim text.